Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared Mostafa Faisal Mohammed Saleh’s post on LinkedIn, adding:
”Honored to contribute to this review published in Current Oncology MDPI, evaluating a decade of evidence on second or salvage autologous stem cell transplantation in relapsed multiple myeloma.
This work reinforces that ASCT2 remains a clinically meaningful, risk-adapted option for selected patients, particularly those with prolonged first remission and chemosensitive relapse, even in the era of CAR-T and bispecific antibodies.
Grateful to collaborate with distinguished colleagues Marwa Nassar, Nourah Alzaidy, Amr Hanbali, Mahmoud Aljurf, and Mostafa Faisal Mohammed Saleh.
It was a privilege to work together on this important analysis.”
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our recent review just out in Current Oncology: ASCT2 in relapsed MM (2016 – 2026) across14 key studies.
Feasible and safe: NRM 1–4% (day 100–1y) across large registries (n=305–975).
Median PFS 9.8–30.2 mo; OS ~30 to >80 mo depending on risk.
Interval ≥24 mo from ASCT1 = strongest predictor → PFS 17–45 mo; OS >60–80 mo in favorable subsets.
Maintenance matters: lenalidomide PFS 41 vs 21.6 mo; carfilzomib-dex TTP 25.1 vs 16.7 mo.
Phase III GMMG ReLApsE: no PFS/OS superiority (20.5 vs 19.3 mo; OS 67.1 vs 62.7) → selection is key.
In the CAR-T/bispecific era, ASCT2 = risk-adapted consolidation or bridge — not routine salvage.”
Title: Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review
Authors: Marwa Nassar, Nourah Alzaidy, Abdulrahman Nasiri, Amr Hanbali, Mahmoud A. Aljurf, Mostafa F. Mohammed Saleh
Read the Full Article on Current Oncology․
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 17:19Ralf Ludwig: Bridging Population Data and Immunology in Inflammatory Diseases
-
Apr 22, 2026, 17:15Giacomo Rossi: Genetic Study Reveals 10 Genes in Hyperemesis Gravidarum
-
Apr 22, 2026, 17:06Maura Boerio: Quantifying Barriers to Care in Vascular Ehlers-Danlos Syndrome
-
Apr 22, 2026, 17:05Kausik Ray։ Metabolically Healthy Obesity Is Being Re-Evaluated as a High-Risk Condition Needing Closer Attention
-
Apr 22, 2026, 16:58Baba-Jallah Epega: Sickle Cell Resilience Through Patient Voices and Clinical Insight
-
Apr 22, 2026, 16:44Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
-
Apr 22, 2026, 16:29CBTH 2026 Opens with First Workshop in Germany – European Hematology Association
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL